Korsana Biosciences, Inc. KRSA
Korsana Biosciences, Inc. (Nasdaq: KRSA) is a CNS/neurology/psychiatry drug developer. Its lead program, CYC-126, is in Pre-clinical for treatment-resistant depression (propofol + dexmedetomidine with personalized delivery/monitoring system).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| praliciguat (out-licensed to Akebia) | focal segmental glomerulosclerosis (Akebia-sponsored Phase 2) | small molecule | Phase 2 |
| zagociguat (sold to Tisento; company holds ~10% equity) | MELAS (Tisento-sponsored Phase 2b PRIZM, enrollment complete Jan 2026) | small molecule | Phase 2 |
| CYC-126 | treatment-resistant depression (Phase 2 in Australia was planned for 2H 2026; 10-Q says integrated clinical/regulatory/commercial strategy suspended due to cash limitations) | small molecule | Pre-clinical |
| olinciguat (sGC stimulator, wholly owned, seeking licensee) | vascular/cardio-renal indications; no active trial disclosed | small molecule | Pre-clinical |
Recent results and decisions
- Feb 17, 2026positive Received positive written pre-IND feedback from FDA supporting the planned CYC-126 Phase 2 POC study design in TRD.
announced it has received positive written regulatory feedback and responses from the FDA on CYC-126’s Phase 2 POC study in TRD and its path to potential regulatory approval
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.